Access count of this item: 115

Files in This Item:
File Description SizeFormat 
31_769.pdf298.7 kBAdobe PDFView/Open
Title: 膀胱癌再発に対するBleomycin加温水灌流療法の効果
Other Titles: Effect of hyperthermic irrigation with bleomycin on prophylaxis of recurrence of bladder cancer
Authors: 西村, 一男  KAKEN_name
小川, 修  kyouindb  KAKEN_id
吉村, 直樹  KAKEN_name
中川, 隆  KAKEN_name
佐々木, 美晴  KAKEN_name
Author's alias: NISHIMURA, Kazuo
OGAWA, Osamu
YOSHIMURA, Naoki
NAKAGAWA, Takashi
SASAKI, Miharu
Keywords: Hyperthermic irrigation with Bleomycin
Bladder cancer
Prophylactic effect
Issue Date: May-1985
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 31
Issue: 5
Start page: 769
End page: 773
Abstract: 1978年4月~1984年5月の間に,ブレオ温水灌流を施行した回数は,延べ83回で,うち,初発表在性膀胱腫瘍に対し,術後,再発予防を目的とし施行したのは,54例であった.初発表在性膀胱腫瘍54例中10例が再発した.actual methodにより算出した非再発率は,1年88.0%,2と3年73.3%,4年以上63.5%で,recurrence rate per 100 patient-monthsは0.98で,いずれも他の報告と同等もしくは良好であった.副作用は57.8%に認め,いずれも局所副作用のみで,重篤な副作用は,1例もなかった.ブレオ温水灌流は,患者の負担は少なく,また安全性も高く有用な方法と思われる
Hyperthermic irrigation with Bleomycin of bladder at 43 approximately 44 degrees C for 3 hours after operation was performed in about 80 cases of bladder cancer from 1978, in our hospital. Bleomycin (90 mg) in 3,000 ml saline solution, was irrigated for 10 days postoperatively. No severe side effect was observed, while the complaint of a local side effect (bladder irritability) was made in 57.8%. Non-recurrence rate was calculated by the actual method, in 54 patients with bladder cancer which occurred initially. Non recurrence rate was 88.0% after 1 year, 73.3% after 2 and 3 years, and 63.5% after 4 years or more. Recurrence rate per 100 patient-month was 0.98. On the basis of our observations, it was concluded that hyperthermic irrigation with Bleomycin was useful for the prophylaxis for recurrence of bladder cancer after removal of the tumor.
URI: http://hdl.handle.net/2433/118495
PubMed ID: 2413744
Appears in Collections:Vol.31 No.5

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.